211 related articles for article (PubMed ID: 19146393)
1. Reaction of Mycobacterium tuberculosis cytochrome P450 enzymes with nitric oxide.
Ouellet H; Lang J; Couture M; Ortiz de Montellano PR
Biochemistry; 2009 Feb; 48(5):863-72. PubMed ID: 19146393
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs.
Ouellet H; Podust LM; de Montellano PR
J Biol Chem; 2008 Feb; 283(8):5069-80. PubMed ID: 18089574
[TBL] [Abstract][Full Text] [Related]
3. Structure Based Discovery of Inhibitors of CYP125 and CYP142 from Mycobacterium tuberculosis.
Katariya MM; Snee M; Tunnicliffe RB; Kavanagh ME; Boshoff HIM; Amadi CN; Levy CW; Munro AW; Abell C; Leys D; Coyne AG; McLean KJ
Chemistry; 2023 May; 29(29):e202203868. PubMed ID: 36912255
[TBL] [Abstract][Full Text] [Related]
4. The Structure of Mycobacterium tuberculosis CYP125: molecular basis for cholesterol binding in a P450 needed for host infection.
McLean KJ; Lafite P; Levy C; Cheesman MR; Mast N; Pikuleva IA; Leys D; Munro AW
J Biol Chem; 2009 Dec; 284(51):35524-33. PubMed ID: 19846552
[TBL] [Abstract][Full Text] [Related]
5. Expression and characterization of Mycobacterium tuberculosis CYP144: common themes and lessons learned in the M. tuberculosis P450 enzyme family.
Driscoll MD; McLean KJ; Cheesman MR; Jowitt TA; Howard M; Carroll P; Parish T; Munro AW
Biochim Biophys Acta; 2011 Jan; 1814(1):76-87. PubMed ID: 20621636
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
Podust LM; von Kries JP; Eddine AN; Kim Y; Yermalitskaya LV; Kuehne R; Ouellet H; Warrier T; Alteköster M; Lee JS; Rademann J; Oschkinat H; Kaufmann SH; Waterman MR
Antimicrob Agents Chemother; 2007 Nov; 51(11):3915-23. PubMed ID: 17846131
[TBL] [Abstract][Full Text] [Related]
7. Interaction of nitric oxide with cytochrome P450 BM3.
Quaroni LG; Seward HE; McLean KJ; Girvan HM; Ost TW; Noble MA; Kelly SM; Price NC; Cheesman MR; Smith WE; Munro AW
Biochemistry; 2004 Dec; 43(51):16416-31. PubMed ID: 15610036
[TBL] [Abstract][Full Text] [Related]
8. Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen.
Driscoll MD; McLean KJ; Levy C; Mast N; Pikuleva IA; Lafite P; Rigby SE; Leys D; Munro AW
J Biol Chem; 2010 Dec; 285(49):38270-82. PubMed ID: 20889498
[TBL] [Abstract][Full Text] [Related]
9. CYP121, CYP51 and associated redox systems in Mycobacterium tuberculosis: towards deconvoluting enzymology of P450 systems in a human pathogen.
McLean KJ; Dunford AJ; Sabri M; Neeli R; Girvan HM; Balding PR; Leys D; Seward HE; Marshall KR; Munro AW
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1178-82. PubMed ID: 17073780
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the bacterial CYP51 cytochrome P450 enzymes from Mycobacterium marinum and Mycobacterium tuberculosis.
Mohamed H; Child SA; Bruning JB; Bell SG
J Steroid Biochem Mol Biol; 2022 Jul; 221():106097. PubMed ID: 35346833
[TBL] [Abstract][Full Text] [Related]
11. The binding of nitrogen-donor ligands to the ferric and ferrous forms of cytochrome P450 enzymes.
Mohamed H; Ghith A; Bell SG
J Inorg Biochem; 2023 May; 242():112168. PubMed ID: 36870164
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide dioxygenation reaction in DevS and the initial response to nitric oxide in Mycobacterium tuberculosis.
Yukl ET; Ioanoviciu A; Sivaramakrishnan S; Nakano MM; Ortiz de Montellano PR; Moënne-Loccoz P
Biochemistry; 2011 Feb; 50(6):1023-8. PubMed ID: 21250657
[TBL] [Abstract][Full Text] [Related]
13. Engineering a self-sufficient Mycobacterium tuberculosis CYP130 by gene fusion with the reductase-domain of CYP102A1 from Bacillus megaterium.
Ortega Ugalde S; Luirink RA; Geerke DP; Vermeulen NPE; Bitter W; Commandeur JNM
J Inorg Biochem; 2018 Mar; 180():47-53. PubMed ID: 29232638
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterial cytochrome p450 125 (cyp125) catalyzes the terminal hydroxylation of c27 steroids.
Capyk JK; Kalscheuer R; Stewart GR; Liu J; Kwon H; Zhao R; Okamoto S; Jacobs WR; Eltis LD; Mohn WW
J Biol Chem; 2009 Dec; 284(51):35534-42. PubMed ID: 19846551
[TBL] [Abstract][Full Text] [Related]
15. Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.
Ortiz de Montellano PR
J Inorg Biochem; 2018 Mar; 180():235-245. PubMed ID: 29352597
[TBL] [Abstract][Full Text] [Related]
16. Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.
Podust LM; Ouellet H; von Kries JP; de Montellano PR
J Biol Chem; 2009 Sep; 284(37):25211-9. PubMed ID: 19605350
[TBL] [Abstract][Full Text] [Related]
17. Impact of distal side water and residue 315 on ligand binding to ferric Mycobacterium tuberculosis catalase-peroxidase (KatG).
Ranguelova K; Suarez J; Metlitsky L; Yu S; Brejt SZ; Brejt SZ; Zhao L; Schelvis JP; Magliozzo RS
Biochemistry; 2008 Nov; 47(47):12583-92. PubMed ID: 18956888
[TBL] [Abstract][Full Text] [Related]
18. Rapid P450 heme iron reduction by laser photoexcitation of Mycobacterium tuberculosis CYP121 and CYP51B1. Analysis of CO complexation reactions and reversibility of the P450/P420 equilibrium.
Dunford AJ; McLean KJ; Sabri M; Seward HE; Heyes DJ; Scrutton NS; Munro AW
J Biol Chem; 2007 Aug; 282(34):24816-24. PubMed ID: 17553785
[TBL] [Abstract][Full Text] [Related]
19. The Mycobacterium tuberculosis cytochromes P450: physiology, biochemistry & molecular intervention.
McLean KJ; Belcher J; Driscoll MD; Fernandez CC; Le Van D; Bui S; Golovanova M; Munro AW
Future Med Chem; 2010 Aug; 2(8):1339-53. PubMed ID: 21426022
[TBL] [Abstract][Full Text] [Related]
20. Resonance Raman investigations of Escherichia coli-expressed Pseudomonas putida cytochrome P450 and P420.
Wells AV; Li P; Champion PM; Martinis SA; Sligar SG
Biochemistry; 1992 May; 31(18):4384-93. PubMed ID: 1581294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
